Chickpea - I am with you. If we can repeat similar chart patterns like we have last two days, even with lower trajectory, we will see above $1 at the end of today.
IMO, once ONCS can generate solid data, ONCS will be partnered or acquired. With very competitive nature in I-O, big pharma may invest at the first sign instead wait until the completion to avoid bidding war. The ability for PD-1 inhibitors to Cross over the solid tumors likely require combination therapy with other I-O technologies and IL-12 seems to be the appropriate candidate.
We got general understanding of the company milestone but we just don't know unadvertised upcoming catalysts and that's why I am staying in all the time.
News 
Market Data 
Discover 
